Pharmaceutical

Pfizer sets sights on Summit’s bispecific in combo with its ADCs

Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s ivonescimab in combination with several of its ADCs.

Feb 25, 2025 - 06:00
Pfizer sets sights on Summit’s bispecific in combo with its ADCs
Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s ivonescimab in combination with several of its ADCs.
Read the original article

Tags:

Previous Article

FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancer

Next Article

EC authorises Celltrion’s Avtozma for multiple indications

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How the first Native Hawaiian psychiatrist set a course for diversifying medicine

How the first Native Hawaiian psychiatrist set a course...

Aug 23, 2023

Listen: The FTC v. Amgen, Sarepta’s future, & Galapagos’ turnaround

Listen: The FTC v. Amgen, Sarepta’s future, & Galapagos...

May 19, 2023

Rejuvenate and SAS partner to harness AI for age-related diseases

Rejuvenate and SAS partner to harness AI for age-relate...

Aug 3, 2024